![](/wp-content/uploads/2018/10/MBqrEZ1tTXuvq4EaPRhp.png)
$599
Novo acquires Ziylo for glucose responsive insulin development
Novo announced (press release) the acquisition of Ziylo, a small incubator company based out of the University of Bristol developing synthetic glucose binding molecules. The purchase of Ziylo aligns with Novo’s strategic goal of developing glucose responsive insulin.